{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:05:40Z","timestamp":1793862340638,"version":"4.6.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Great Ormond Street Hospital Biomedical Research Centre"},{"DOI":"10.13039\/100030827","name":"NHS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004856","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To elicit and quantify expert opinion concerning the relative merits of two treatments for a rare inflammatory disease: JDM. The formal expression of expert opinion reported in this article will be used in a Bayesian analysis of a forthcoming randomized controlled trial known as BARJDM (baricitinib for JDM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A Bayesian prior elicitation meeting was convened, following a previously described methodological template. Opinion was sought on the probability that a patient in the BARJDM trial would achieve clinically inactive disease, off glucocorticoids (GC) within a 12-month period with either MTX (standard of care); or baricitinib (a Janus kinase inhibitor, JAKi), with GC schedules identical in both arms of the trial. Experts\u2019 views were discussed and refined following presentation and further discussion of summated published data regarding efficacy of MTX or JAKi for JDM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten UK paediatric rheumatology consultants (including one adolescent paediatric rheumatologist) participated in the elicitation meeting. All had expertise in JDM, leading active National Health Service clinics for this disease. Consensus expert prior opinion was that the most likely probability of clinically inactive disease off GC within 12\u2009months was 0.55 on baricitinib and 0.23 on MTX, with a greater degree of uncertainty for baricitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Experts currently think that baricitinib is superior to MTX for the treatment of JDM, although there is uncertainty around this. BARJDM will therefore integrate randomized trial data with this expert prior opinion to derive a posterior distribution for the relative efficacy of baricitinib compared with MTX.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae392","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:25:47Z","timestamp":1722047147000},"page":"3271-3278","source":"Crossref","is-referenced-by-count":9,"title":["Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1237-0557","authenticated-orcid":false,"given":"Charalampia","family":"Papadopoulou","sequence":"first","affiliation":[{"name":"Paediatric Rheumatology Department, Great Ormond Street Hospital for Children, NHS Foundation Trust , London,","place":["UK"]},{"name":"Inflammation and Rheumatology Section, University College London Great Ormond Street Institute of Child Health , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martin","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, The Royal Hospital for Children , Glasgow,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rafiq","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, The Evelina London Children\u2019s Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"McCann","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Alder Hey Children\u2019s Hospital , Liverpool,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-5960","authenticated-orcid":false,"given":"Giulia","family":"Varner","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Royal Manchester Children\u2019s Hospital , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Nott","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Southampton Children\u2019s Hospital , Southampton,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Compeyrot-Lacassagne","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Great Ormond Street Hospital for Children, NHS Foundation Trust , London,","place":["UK"]},{"name":"Inflammation and Rheumatology Section, University College London Great Ormond Street Institute of Child Health , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Leandro","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University College London Hospital , London,","place":["UK"]},{"name":"Centre for Rheumatology, University College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Foley","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, The Evelina London Children\u2019s Hospital , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Warrier","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Nottingham Children\u2019s Hospital , Nottingham,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2745-1736","authenticated-orcid":false,"given":"Nathan","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Statistical Science, UCL , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Wan","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, The Evelina London Children\u2019s Hospital , London,","place":["UK"]},{"name":"Institute of Pharmaceutical Science, King's College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim-Moulay","family":"Dehbi","sequence":"additional","affiliation":[{"name":"Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-8265","authenticated-orcid":false,"given":"John","family":"Whitehead","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, Lancaster University , Lancaster,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Eleftheriou","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Great Ormond Street Hospital for Children, NHS Foundation Trust , London,","place":["UK"]},{"name":"Inflammation and Rheumatology Section, University College London Great Ormond Street Institute of Child Health , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brogan","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Department, Great Ormond Street Hospital for Children, NHS Foundation Trust , London,","place":["UK"]},{"name":"Inflammation and Rheumatology Section, University College London Great Ormond Street Institute of Child Health , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"2024121300331488900_keae392-B1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024121300331488900_keae392-B2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2024121300331488900_keae392-B3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024121300331488900_keae392-B4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024121300331488900_keae392-B5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/rheumatology\/keq261","article-title":"A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies","volume":"50","author":"Martin","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2024121300331488900_keae392-B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024121300331488900_keae392-B7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T","article-title":"Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis","volume":"43","author":"Huber","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2024121300331488900_keae392-B8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12969-016-0118-0","article-title":"Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study","volume":"14","author":"Okong'o","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024121300331488900_keae392-B9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2024121300331488900_keae392-B10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1756-185X.13759","article-title":"Long-term outcome in children with juvenile dermatomyositis: a single-center study from north India","volume":"23","author":"Sharma","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2024121300331488900_keae392-B11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2019.06.014","article-title":"Long-term outcomes in Juvenile Myositis patients","volume":"50","author":"Tsaltskan","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2024121300331488900_keae392-B12","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024121300331488900_keae392-B13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/03009742.2011.608376","article-title":"Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study","volume":"41","author":"Mathiesen","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2024121300331488900_keae392-B14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/art.24343","article-title":"Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study","volume":"61","author":"Apaz","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024121300331488900_keae392-B15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12969-022-00754-y","article-title":"Juvenile dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective","volume":"20","author":"Boros","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024121300331488900_keae392-B16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/art.41639","article-title":"The vasculopathy of juvenile dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness","volume":"73","author":"Papadopoulou","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024121300331488900_keae392-B17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kex465","article-title":"Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample","volume":"57","author":"Silverberg","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2024121300331488900_keae392-B18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"2024121300331488900_keae392-B19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024121300331488900_keae392-B20","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1093\/rheumatology\/keac107","article-title":"Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study","volume":"61","author":"Dabbak","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2024121300331488900_keae392-B21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-021-00990-3","article-title":"Use of rescue therapy with IVIG or cyclophosphamide in juvenile myositis","volume":"23","author":"Doudouliaki","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2024121300331488900_keae392-B22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13696998.2019.1606813","article-title":"Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan","volume":"22","author":"Chen","year":"2019","journal-title":"J Med Econ"},{"key":"2024121300331488900_keae392-B23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024121300331488900_keae392-B24","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"2024121300331488900_keae392-B25","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"key":"2024121300331488900_keae392-B26","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"key":"2024121300331488900_keae392-B27","doi-asserted-by":"crossref","first-page":"e0120981","DOI":"10.1371\/journal.pone.0120981","article-title":"Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa","volume":"10","author":"Hampson","year":"2015","journal-title":"PLoS One"},{"key":"2024121300331488900_keae392-B28","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1002\/sim.6225","article-title":"Bayesian methods for the design and interpretation of clinical trials in very rare diseases","volume":"33","author":"Hampson","year":"2014","journal-title":"Stat Med"},{"key":"2024121300331488900_keae392-B29","doi-asserted-by":"crossref","first-page":"e0215739","DOI":"10.1371\/journal.pone.0215739","article-title":"Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: an example of a proposed trial of adalimumab versus pamidronate for children with CNO\/CRMO","volume":"14","author":"Ramanan","year":"2019","journal-title":"PLoS One"},{"key":"2024121300331488900_keae392-B30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12688\/amrcopenres.13008.1","article-title":"Prior elicitation of the efficacy and tolerability of methotrexate and mycophenolate mofetil in juvenile localised scleroderma","volume":"3","author":"Desai","year":"2021","journal-title":"AMRC Open Res"},{"key":"2024121300331488900_keae392-B31","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/art.41730","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in childhood polyarteritis nodosa: an open-label, randomized, Bayesian noninferiority trial","volume":"73","author":"Brogan","year":"2021","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae392\/58749871\/keae392.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/12\/3271\/60903477\/keae392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/12\/3271\/60903477\/keae392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:33:34Z","timestamp":1734050014000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/12\/3271\/7723495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,7,29]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae392","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,29]]}}}